دورية أكاديمية
Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
| العنوان: | Quisinostat is a brain-penetrant radiosensitizer in glioblastoma |
|---|---|
| المؤلفون: | Lo Cascio, Costanza, Margaryan, Tigran, Luna-Melendez, Ernesto, McNamara, James B, White, Connor I, Knight, William, Ganta, Saisrinidhi, Opachich, Zorana, Cantoni, Claudia, Yoo, Wonsuk, Sanai, Nader, Tovmasyan, Artak, Mehta, Shwetal |
| المصدر: | Translational Neuroscience |
| بيانات النشر: | Barrow - St. Joseph's Scholarly Commons |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Brain cancer, Drug therapy, Oncology, Radiation therapy, Therapeutics, Adult, Humans, Child, Histone Deacetylase Inhibitors (pharmacology, therapeutic use), Glioblastoma (drug therapy, radiotherapy), Hydroxamic Acids (pharmacology, Histone Deacetylases (metabolism), Brain Neoplasms (drug therapy, Protein Isoforms (metabolism), Brain (metabolism) |
| الوصف: | Histone deacetylase (HDAC) inhibitors have garnered considerable interest for the treatment of adult and pediatric malignant brain tumors. However, owing to their broad-spectrum nature and inability to effectively penetrate the blood-brain barrier, HDAC inhibitors have failed to provide substantial clinical benefit to patients with glioblastoma (GBM) to date. Moreover, global inhibition of HDACs results in widespread toxicity, highlighting the need for selective isoform targeting. Although no isoform-specific HDAC inhibitors are currently available, the second-generation hydroxamic acid-based HDAC inhibitor quisinostat possesses subnanomolar specificity for class I HDAC isoforms, particularly HDAC1 and HDAC2. It has been shown that HDAC1 is the essential HDAC in GBM. This study analyzed the neuropharmacokinetic, pharmacodynamic, and radiation-sensitizing properties of quisinostat in preclinical models of GBM. It was found that quisinostat is a well-tolerated and brain-penetrant molecule that extended survival when administered in combination with radiation in vivo. The pharmacokinetic-pharmacodynamic-efficacy relationship was established by correlating free drug concentrations and evidence of target modulation in the brain with survival benefit. Together, these data provide a strong rationale for clinical development of quisinostat as a radiosensitizer for the treatment of GBM. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://scholar.barrowneuro.org/neurobiology/2362Test; https://doi.org/10.1172/jci.insight.167081Test |
| DOI: | 10.1172/jci.insight.167081 |
| الإتاحة: | https://doi.org/10.1172/jci.insight.167081Test https://scholar.barrowneuro.org/neurobiology/2362Test |
| رقم الانضمام: | edsbas.4FC57944 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.4FC57944 975 3 Academic Journal academicJournal 975.149597167969 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.4FC57944&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1172/jci.insight.167081# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Lo+Cascio%2C+Costanza%22">Lo Cascio, Costanza</searchLink><br /><searchLink fieldCode="AR" term="%22Margaryan%2C+Tigran%22">Margaryan, Tigran</searchLink><br /><searchLink fieldCode="AR" term="%22Luna-Melendez%2C+Ernesto%22">Luna-Melendez, Ernesto</searchLink><br /><searchLink fieldCode="AR" term="%22McNamara%2C+James+B%22">McNamara, James B</searchLink><br /><searchLink fieldCode="AR" term="%22White%2C+Connor+I%22">White, Connor I</searchLink><br /><searchLink fieldCode="AR" term="%22Knight%2C+William%22">Knight, William</searchLink><br /><searchLink fieldCode="AR" term="%22Ganta%2C+Saisrinidhi%22">Ganta, Saisrinidhi</searchLink><br /><searchLink fieldCode="AR" term="%22Opachich%2C+Zorana%22">Opachich, Zorana</searchLink><br /><searchLink fieldCode="AR" term="%22Cantoni%2C+Claudia%22">Cantoni, Claudia</searchLink><br /><searchLink fieldCode="AR" term="%22Yoo%2C+Wonsuk%22">Yoo, Wonsuk</searchLink><br /><searchLink fieldCode="AR" term="%22Sanai%2C+Nader%22">Sanai, Nader</searchLink><br /><searchLink fieldCode="AR" term="%22Tovmasyan%2C+Artak%22">Tovmasyan, Artak</searchLink><br /><searchLink fieldCode="AR" term="%22Mehta%2C+Shwetal%22">Mehta, Shwetal</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Translational Neuroscience ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Barrow - St. Joseph's Scholarly Commons ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Brain+cancer%22">Brain cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+therapy%22">Drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Radiation+therapy%22">Radiation therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Child%22">Child</searchLink><br /><searchLink fieldCode="DE" term="%22Histone+Deacetylase+Inhibitors+%28pharmacology%22">Histone Deacetylase Inhibitors (pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22therapeutic+use%29%22">therapeutic use)</searchLink><br /><searchLink fieldCode="DE" term="%22Glioblastoma+%28drug+therapy%22">Glioblastoma (drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22radiotherapy%29%22">radiotherapy)</searchLink><br /><searchLink fieldCode="DE" term="%22Hydroxamic+Acids+%28pharmacology%22">Hydroxamic Acids (pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Histone+Deacetylases+%28metabolism%29%22">Histone Deacetylases (metabolism)</searchLink><br /><searchLink fieldCode="DE" term="%22Brain+Neoplasms+%28drug+therapy%22">Brain Neoplasms (drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Protein+Isoforms+%28metabolism%29%22">Protein Isoforms (metabolism)</searchLink><br /><searchLink fieldCode="DE" term="%22Brain+%28metabolism%29%22">Brain (metabolism)</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Histone deacetylase (HDAC) inhibitors have garnered considerable interest for the treatment of adult and pediatric malignant brain tumors. However, owing to their broad-spectrum nature and inability to effectively penetrate the blood-brain barrier, HDAC inhibitors have failed to provide substantial clinical benefit to patients with glioblastoma (GBM) to date. Moreover, global inhibition of HDACs results in widespread toxicity, highlighting the need for selective isoform targeting. Although no isoform-specific HDAC inhibitors are currently available, the second-generation hydroxamic acid-based HDAC inhibitor quisinostat possesses subnanomolar specificity for class I HDAC isoforms, particularly HDAC1 and HDAC2. It has been shown that HDAC1 is the essential HDAC in GBM. This study analyzed the neuropharmacokinetic, pharmacodynamic, and radiation-sensitizing properties of quisinostat in preclinical models of GBM. It was found that quisinostat is a well-tolerated and brain-penetrant molecule that extended survival when administered in combination with radiation in vivo. The pharmacokinetic-pharmacodynamic-efficacy relationship was established by correlating free drug concentrations and evidence of target modulation in the brain with survival benefit. Together, these data provide a strong rationale for clinical development of quisinostat as a radiosensitizer for the treatment of GBM. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => text ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => unknown ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://scholar.barrowneuro.org/neurobiology/2362; https://doi.org/10.1172/jci.insight.167081 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1172/jci.insight.167081 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1172/jci.insight.167081<br />https://scholar.barrowneuro.org/neurobiology/2362 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.4FC57944 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1172/jci.insight.167081
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => unknown
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Brain cancer
[Type] => general
)
[1] => Array
(
[SubjectFull] => Drug therapy
[Type] => general
)
[2] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[3] => Array
(
[SubjectFull] => Radiation therapy
[Type] => general
)
[4] => Array
(
[SubjectFull] => Therapeutics
[Type] => general
)
[5] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[6] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[7] => Array
(
[SubjectFull] => Child
[Type] => general
)
[8] => Array
(
[SubjectFull] => Histone Deacetylase Inhibitors (pharmacology
[Type] => general
)
[9] => Array
(
[SubjectFull] => therapeutic use)
[Type] => general
)
[10] => Array
(
[SubjectFull] => Glioblastoma (drug therapy
[Type] => general
)
[11] => Array
(
[SubjectFull] => radiotherapy)
[Type] => general
)
[12] => Array
(
[SubjectFull] => Hydroxamic Acids (pharmacology
[Type] => general
)
[13] => Array
(
[SubjectFull] => Histone Deacetylases (metabolism)
[Type] => general
)
[14] => Array
(
[SubjectFull] => Brain Neoplasms (drug therapy
[Type] => general
)
[15] => Array
(
[SubjectFull] => Protein Isoforms (metabolism)
[Type] => general
)
[16] => Array
(
[SubjectFull] => Brain (metabolism)
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lo Cascio, Costanza
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Margaryan, Tigran
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Luna-Melendez, Ernesto
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => McNamara, James B
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => White, Connor I
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Knight, William
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ganta, Saisrinidhi
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Opachich, Zorana
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cantoni, Claudia
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yoo, Wonsuk
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sanai, Nader
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tovmasyan, Artak
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mehta, Shwetal
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Translational Neuroscience
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |